This includes mental health deterioration, memory problems, sensory issues, and sensations of pain
Aucatzyl is the first CAR T therapy to be approved without a Risk Evaluation Mitigation Strategy program requirement
After treatment for decreasing intracranial pressure (mannitol 2 g/kg constant rate infusion for 30 min, furosemide 1 mg/kg IV), his conscious level recovered, his respiratory state stabilized, and he was discharged
Comprising Delta Sleep-Inducing Peptide, DSIP Sprays are intended for research purposes only
GeneDxs adjusted net income figure removes restructuring costs, depreciation and amortization, and stock-based compensation
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ